Ying Huang, Legend Biotech CEO
May 27, 2021 08:50 AM EDT
Cell/Gene Tx
FDA+

FDA steers J&J/Leg­end CAR-T to a quick de­ci­sion as part­ners prep a loom­ing show­down with Bris­tol My­ers, blue­bird

John Carroll

Editor & Founder

Just days af­ter in­ves­ti­ga­tors post­ed a jaw-drop­ping set of pos­i­tive up­dat­ed da­ta for the BC­MA CAR-T cil­ta-cel — or JNJ-4528 — J&J’s part­ners at Leg­end are …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times